Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics - PubMed
5 hours ago
- #cytogenetics
- #AML
- #chemotherapy
- Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics was studied.
- 358 newly diagnosed AML-vHRC cases were analyzed, with 60% treated with HMA+ven and 40% with IC.
- Median overall survival (OS) for AML-vHRC was 8 months compared to 31 months for non-vHRC AML.
- Composite complete remission (cCR) rates were similar between IC and HMA+ven (55% vs 54%).
- Patients with inv(3)/t(3;3) had inferior responses (cCR 36%) compared to CK/MK-AML (67%).
- No OS differences were observed by frontline regimen among patients aged 60-75 years, those with TP53-mutated disease, or following alloHSCT.
- Older age, inv(3)/t(3;3), and TP53 mutations independently predicted inferior OS, while alloHSCT improved OS.
- HMA+ven represents a reasonable frontline option for patients aged 60-75 years, those with TP53mt disease, and patients intended for alloHSCT.